Prana Biotechnology Limited (NASDAQ:PRAN) has been assigned an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports.
Analysts have set a one year consensus price objective of $4.00 for the company, according to Zacks. Zacks has also given Prana Biotechnology an industry rank of 50 out of 255 based on the ratings given to its competitors.
Separately, ValuEngine raised shares of Prana Biotechnology from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st.
NASDAQ:PRAN opened at $1.61 on Wednesday. The stock has a market capitalization of $14.04 million, a PE ratio of -2.30 and a beta of 1.01. Prana Biotechnology has a fifty-two week low of $1.09 and a fifty-two week high of $3.01.
About Prana Biotechnology
Prana Biotechnology Limited researches and develops therapeutic drugs for the treatment of Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidates include PBT434 that is in Phase I clinical trial for the treatment for Parkinson's disease and other movement disorders; and PBT2, which has completed four Phase I studies and a Phase IIa clinical trial for patients with Alzheimer's disease.
Read More: Relative Strength Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Prana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.